Generic Doryx MPC Availability
Last updated on Apr 10, 2025.
See also: Generic Doryx
Doryx MPC is a brand name of doxycycline, approved by the FDA in the following formulation(s):
DORYX MPC (doxycycline hyclate - tablet, delayed release;oral)
-
Manufacturer: MAYNE PHARMA
Approval date: May 20, 2016
Strength(s): EQ 60MG BASE [RLD], EQ 120MG BASE (discontinued) [RLD]
Is there a generic version of Doryx MPC available?
An Authorized Generic version of Doryx MPC has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.
List of authorized generic versions:
- Doxycycline Hyclate ORAL TABLET, DELAYED RELEASE 80 mg
Mayne Pharma Commercial LLC
NDC Code: 518620571 - Doxycycline Hyclate ORAL TABLET, DELAYED RELEASE 200 mg
Mayne Pharma Commercial LLC
NDC Code: 683080716
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Doryx MPC. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Tabletting process
Patent 8,715,724
Issued: May 6, 2014
Inventor(s): Lukas Stefan
Assignee(s): Mayne Pharma International Pty LtdA process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Preferred anti static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate.
Patent expiration dates:
- February 3, 2028✓
- February 3, 2028
-
Controlled release doxycycline
Patent 9,295,652
Issued: March 29, 2016
Inventor(s): Lukas Stefan & Lepore Angelo & Mudge Stuart
Assignee(s): Mayne Pharma International Pty. Ltd.The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation.
Patent expiration dates:
- October 23, 2034✓✓
- October 23, 2034
-
Controlled release doxycycline
Patent 9,446,057
Issued: September 20, 2016
Inventor(s): Lukas Stefan & Lepore Angelo & Mudge Stuart
Assignee(s): Mayne Pharma International Pty. Ltd.The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation.
Patent expiration dates:
- December 23, 2034✓✓
- December 23, 2034
-
Controlled release doxycycline
Patent 9,511,031
Issued: December 6, 2016
Inventor(s): Lukas Stefan & Lepore Angelo & Mudge Stuart
Assignee(s): Mayne Pharma International Pty. Ltd.The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduced side effects such as nausea and irritation.
Patent expiration dates:
- October 23, 2034✓
- October 23, 2034
More about Doryx MPC (doxycycline)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy or Breastfeeding
- En español
Patient resources
Other brands
Vibramycin, Monodox, Doryx, Oracea, ... +7 more
Professional resources
Other brands
Vibramycin, Monodox, Doryx, Oracea, ... +7 more
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
